hrp0082p2-d3-441 | Growth Hormone (2) | ESPE2014

Effects of Gender and Gestational Age on GH Treatment in Very Young Children Born Small for Gestational Age

Boguszewski Margaret , Lindberg Anders , Wollmann Hartmut A

Background: Children born small for gestational age (SGA) with poor growth during the first years of life often remain with short stature during childhood and as adults.Objective and hypotheses: To evaluate the effects of gender and gestational age (GA) on outcomes of GH treatment in very young children born SGA.Method: 620 short SGA children on GH treatment enrolled in KIGS (The Pfizer International Growth Database) were analysed:...

hrp0086p2-p848 | Syndromes: Mechanisms and Management P2 | ESPE2016

Growth of Children Born Preterm During the First 8 Years of Life

Cardoso-Demartini Adriane , da Silva Regina Cavalcante , de Lara Francisca , Boguszewski Margaret

Background: Approximately 15 million children are born preterm worldwide yearly.Objective and hypotheses: To evaluate spontaneous growth during the first 8 years of life.Hypotheses: Preterm born children have spontaneous recovery of weight and height in the first 8 years of life.Method: Measurements at birth, 6, 12 and 24 months of corrected age and at recall [6.4±0.5 years (5.2–8.0)]. Weight, lengt...

hrp0097p1-343 | Pituitary, Neuroendocrinology and Puberty | ESPE2023

Facilitating Transition of Care Into Adulthood in Brain Cancer Survivors With Acquired Pediatric Growth Hormone Deficiency: Insights From an Advisory Board

Alter Craig , Boguszewski Margaret , Clemmons David , Dobri Georgiana , Geffner Mitchell , Kelepouris Nicky , Miller Bradley , Oh Rich , Shea Heidi , Yuen

Kevin

Childhood cancer survivors (CCS), particularly brain cancer survivors, are at risk of developing growth hormone deficiency (GHD) due to hypothalamic-pituitary damage from direct tumor mass effects or treatment. Optimization of testing, long-term treatment, and monitoring during care transition from pediatric to adult endocrinology providers remain challenging. A group of endocrinology experts convened to discuss these challenges, the risks and benefits of GH therapy in CCS wit...

hrp0086p1-p139 | Bone & Mineral Metabolism P1 | ESPE2016

Dental Effects of Intravenous Bisphosphonate When Administered in Early Infancy

Zacharin Margaret

Background: Osteogenesis imperfecta (OI) is characterized by abnormal bone development with low bone mass and increased bone fragility. Dominant mutations affect synthesis & structure of type 1pro-collagen. Recessive mutations affect post-translational processing or tracking of type 1 pro-collagen. OI may be associated with dentinogenesis imperfecta type 1, for both primary and permanent dentition, particularly primary, manifested as tooth discoloration, reduced enamel thi...

hrp0086p2-p388 | Gonads & DSD P2 | ESPE2016

Fertility Outcomes after Childhood Onset Hypothalamic Hypogonadism

Zacharin Margaret

Background: Childhood onset (CO) hypogonadotrophic hypogonadism (HH), congenital or acquired after midline tumours and their treatment, is reported to have significantly poorer outcomes, in terms of adult spermatogenesis induction and duration of treatment to conception, compared with HH of post pubertal onset. A mixed cohort (youngest aged 26 years) reported median time to conception of 28 months.1 Use of hCG and FSH in adolescence is reported to result in spermato...

hrp0086p2-p577 | Perinatal Endocrinology P2 | ESPE2016

Endocrinologists Have A Role in Moderating Adverse Metabolic Consequences of Early Over Feeding of Children Born IUGR

Zacharin Margaret

Background: Intra uterine growth retardation (IUGR) is well recognized to result in infants born small for gestational age (SGA). Early morbidity is followed by increased lifetime risks for health problems, particularly in the 10% of IUGR infants who fail to catch up. Risks include metabolic syndrome with obesity, insulin resistance, abnormal glucose metabolism, hypertension, dyslipidaemia, T2DM. Rapid weight gain in infancy is associated with increased incidence of later obes...

hrp0086p2-p762 | Pituitary and Neuroendocrinology P2 | ESPE2016

Recovery of Hypothalamic Pituitary Function After Stalk Transection and Panhypopituitarism in an Adolescent

Zacharin Margaret

A 12 year old boy sustained a severe head injury by a passing car whilst crossing the road. Injuries were confined to massive basal skull fracture, right sided blindness, acute onset diabetes insipidus, extradural and subdural bleeding requiring surgical decompression. Pre-operative physical examination revealed a healthy looking boy, height 60th centile for age, Tanner stage III puberty, 10 ml testes bilaterally. MR head demonstrated apparent pituitary stalk transection and r...

hrp0082wg8.4 | GPED | ESPE2014

Inequities of Treatment Options in Developing Countries: Congenital Adrenal Hyperplasia

Zacharin Margaret

Adrenal insufficiency of any cause results in major morbidity and increased lifetime risk for adrenal crisis and potential mortality. A majority of those affected by disorders of either congenital or acquired origin have deficiencies of both glucocorticoid and mineralocorticoid. Preferred replacement treatment for infants, children and adolescents with growth potential is considered to be with hydrocortisone and fludrocortisone.Both medications are advoc...

hrp0095p1-428 | Bone, Growth Plate and Mineral Metabolism | ESPE2022

Extra-articular calcification in an adolescent boy: where history is paramount

Rodrigues Farrah , Zacharin Margaret

A 15-year-old boy, an active sportsperson, presented to an orthopaedic surgeon with a painful left elbow. He had no history of preceding trauma, had full range of motion of his elbow and was systemically well. Imaging demonstrated extra articular calcification at the distal humerus. Serum phosphate was elevated at 2.53mmol/l [1.10-1.80] with calcium 2.48mmol/l [2.10-2.60] and tubular reabsorption of phosphate of 94.6% [82-100%]. He was then referred for endocrine assessment, w...

hrp0095p1-376 | Sex Differentiation, Gonads and Gynaecology, and Sex Endocrinology | ESPE2022

A virilizing ovarian tumour following previous rhabdomyosarcoma, masking ovarian failure

Rodrigues Farrah , Zacharin Margaret

An 11 year 8-month-old girl presented to her oncologist with recent voice change and increased leg hair growth. She had a past history of pelvic rhabdomyosarcoma in 2012, at age 2, with relapse and local metastasis at age 4. Prior to original tumour treatment, oophoropexy had been performed, aiming to prevent ovarian radiation exposure. At time of the new complaint, she was receiving a trial treatment. Puberty was reported to have commenced at age 10, with 6-months of increase...